MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
-$12,253,044
Free Cash flow
-$11,426,613
Unit: Dollar
Positive Cash Flow Breakdown
Proceeds from the march 2026 pub...
Proceeds from sales and maturiti...
Stock-based compensation expense
Others
Negative Cash Flow Breakdown
Net income (loss)
Purchases of investments
Purchases of property, plant and...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-06-30
2026-03-31
2025-12-31
2025-09-30
Net income (loss)
-22,491,115
-18,868,885
-16,860,743
30,134,426
Depreciation and amortization
813,035
730,965
741,593
743,764
Amortization of finance right-of-use assets
21,295
21,705
21,706
21,705
Stock-based compensation expense
7,247,089
5,459,911
3,169,734
800,764
Gain on the sale of equipment
-
2,217
-
-
Net realized and unrealized (gain) loss on equity securities
-
-9,587
9,929
62,829
Net realized gain on debt securities
-
47,089
-
-
Changes in fair value of warrant liabilities
1,110,526
482,474
3,253,435
-66,007,621
Accretion of discounts on investments
-
-10,075
36,864
23,681
Write-off of deferred issuance costs
-
-
261,105
-
Gain in early termination of lease liability
-
7,042
-
-
Other non-cash items, net
-179,000
-
-
-
Accrued interest receivable
288,720
608,280
386,827
559,954
Prepaid expenses and other current assets
-1,190,263
297,263
6,863,069
-2,131,089
Operating lease right-of-use assets and liabilities, net
163,776
74,224
-3,861
-4,124
Accounts payable
674,881
114,119
324,527
335,924
Accrued expense and other current liabilities
1,829,966
-1,194,966
-394,856
-287,490
Net cash used in operating activities
-9,840,870
-14,271,130
-16,776,327
-13,050,023
Proceeds from the sale of equipment
783
2,217
0
0
Purchases of property, plant and equipment
1,585,743
983,257
933,156
-
Purchases of investments
13,012,219
139,262,781
12,043,721
129,868,915
Proceeds from sales and maturities of investments
9,713,855
74,596,145
11,270,722
0
Net cash (used in) provided by investing activities
-4,883,324
-65,647,676
-1,706,155
-129,868,915
Proceeds from the 2025 pipe, net of series b issuance costs
-
-
0
168,729,827
Proceeds from the march 2026 public offering, net of issuance costs
-
79,636,964
-
-
Payment of deferred issuance costs
-
-
758
-
Proceeds from the march 2026 public offering and underwriters' option, net of issuance costs
81,459,000
7,238,000
-
-
Principal payments of notes payable
-
-
0
3
Proceeds from exercised enrollment date and release date warrants
543,000
2,975,000
-
-
Principal payments on finance leases
-
37,388
36,675
35,977
Principal payments on financed director and officer insurance and finance leases
76,000
-
-
-
Proceeds from exercise of stock options
41,884
113,116
-
-
Tax payments for share settlement of restricted stock units
4,429
4,571
4,252
4,881
Net cash provided by (used in) financing activities
2,363,879
89,921,121
-41,685
168,688,966
Effect of exchange rate changes on cash and cash equivalents
107,271
14,729
-397,861
-37,537
Net decrease in cash and cash equivalents
-12,253,044
10,017,044
-18,922,028
25,732,491
Beginning of period
20,519,724
10,502,680
29,424,708
8,897,966
End of period
8,267,000
20,519,724
10,502,680
29,424,708
Page 1
Unit: Dollar. Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Proceeds from the march
2026 public offering...
$81,459,000
Proceeds from exercised
enrollment date and release...
$543,000
Proceeds from exercise of
stock options
$41,884
Net cash provided by
(used in) financing...
$2,363,879
(779.61%↑ Y/Y)
Effect of exchange rate
changes on cash and cash...
$107,271
(-51.66%↓ Y/Y)
Canceled cashflow
$79,680,005
Net decrease in cash
and cash...
-$12,253,044
(-135.38%↓ Y/Y)
Canceled cashflow
$2,471,150
Stock-based compensation
expense
$7,247,089
(484.37%↑ Y/Y)
Accrued expense and
other current...
$1,829,966
(12.69%↑ Y/Y)
Prepaid expenses and
other current assets
-$1,190,263
(-315.13%↓ Y/Y)
Changes in fair value of
warrant liabilities
$1,110,526
Depreciation and
amortization
$813,035
(-46.14%↓ Y/Y)
Accounts payable
$674,881
(-17.93%↓ Y/Y)
Other non-cash items,
net
-$179,000
Amortization of finance
right-of-use assets
$21,295
(-50.95%↓ Y/Y)
Proceeds from sales and
maturities of investments
$9,713,855
(-2.78%↓ Y/Y)
Proceeds from the sale of
equipment
$783
(56.60%↑ Y/Y)
something is missing
-$79,599,576
Principal payments on
financed director and...
$76,000
Tax payments for
share settlement of...
$4,429
(113.75%↑ Y/Y)
Net cash used in
operating activities
-$9,840,870
(34.17%↑ Y/Y)
Net cash (used in)
provided by investing...
-$4,883,324
(-149.48%↓ Y/Y)
Canceled cashflow
$13,066,055
Canceled cashflow
$9,714,638
Net income (loss)
-$22,491,115
Purchases of investments
$13,012,219
(10485.58%↑ Y/Y)
Accrued interest
receivable
$288,720
(625.38%↑ Y/Y)
Operating lease
right-of-use assets and...
$163,776
(375.55%↑ Y/Y)
Purchases of property,
plant and equipment
$1,585,743
Buy us a coffee
SAB Biotherapeutics, Inc. (SABS)
SAB Biotherapeutics, Inc. (SABS)